Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 8—August 2005

Cephalosporin-resistant Pneumococci and Sickle Cell Disease

Martha L. Miller*1, Caroline A. Obert*1, Geli Gao*, Najat C. Daw*, Patricia Flynn*, and Elaine Tuomanen*Comments to Author 
Author affiliations: *St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Main Article

Table 1

Distribution of β-lactam resistance in nasopharyngeal pneumococcal isolates from sickle cell disease patients

Penicillin susceptibility* No. isolates Cefotaxime susceptibility* No. isolates
Sensitive 31 Sensitive 31
Intermediate 24 Sensitive 19
Intermediate 3
Resistant 2
Resistant 9 Intermediate 3
Resistant 6

*Definition of susceptibility per Clinical and Laboratory Standards Institute (formerly NCCLS) guidelines from 1994 and 1995 (10,11). Sensitive, penicillin V MIC<0.06 μg/mL, cefotaxime MIC<0.05 μg/mL; intermediate, penicillin V MIC 0.12–1 μg/mL, cefotaxime MIC 1 μg/mL; resistant, penicillin or cefotaxime MIC>2 μg/mL.

Main Article

1These authors contributed equally to this study.

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.